Kventiax (Quetiapine)

Quetiapine blocks serotonin 5‑HT2A and dopamine D2 receptors while also antagonising histamine H1 and adrenergic α1 receptors. This mixed receptor activity helps reduce psychotic symptoms, stabilise mood, and augment antidepressant effects.

The specific dose of Kventiax is determined by the treating prescriber based on the individual’s diagnosis, severity, response, and tolerability. Only a qualified healthcare professional should set the dosing regimen.

Safety data for quetiapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant and consider alternative therapies when appropriate.

To request Kventiax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kventiax (quetiapine) offers a broader receptor profile, which can provide mood‑stabilising benefits and a lower risk of extrapyramidal symptoms compared with some alternatives. However, it may be associated with higher rates of sedation and metabolic changes, so clinicians choose it based on individual patient needs.

Kventiax should be stored at ambient temperature below 25 °C, in its original packaging, and protected from moisture and direct sunlight to maintain stability.

Kventiax is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include agranulocytosis, neuroleptic malignant syndrome, severe hypotension, seizures, and emergent suicidal thoughts. Patients should be monitored closely for any of these events, especially during treatment initiation or dose changes.

Kventiax is contraindicated in individuals with known hypersensitivity to quetiapine or any of its excipients, and it should be used with caution in patients with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of serious neuroleptic reactions.